News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Learning From Failure: What Theranos, Interleukin Genetics (ILGN), & Courtagen Can Teach Us About IVDs



8/7/2017 6:14:39 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
In the aftermath of the Theranos downfall, dozens of pundits have performed virtual autopsies of where CEO Elizabeth Holmes went wrong, generally highlighting a lack of full disclosure about the technology its labs were using. In the beginning of July, Interleukin Genetics announced that it was laying off more than half of its staff amid a decision to halt sales of its genetic test for periodontal disease risk. Just a few weeks later, Courtagen Life Sciences announced it would no longer offer its next-generation sequencing (NGS)-based tests for neurological disorders due to difficulties with reimbursement and the regulatory environment.

Read at MedCity News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES